Li-Hong Tang alleviates dextran sodium sulfate-induced colitis by regulating NRF2/HO-1 signaling pathway and gut microbiota
Frontiers in Pharmacology · 30.05.2024 · 15
DOI: 10.3389/fphar.2024.1413666 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.05.2024. Verfasst von Hong Gu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangyin Hospital Affiliated to Nanjing University of Chinese Medicine, Jiangyin, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Ulcerative colitis (UC) is marked by recurring inflammation. Existing treatments are ineffective and may have toxic side effects. Thus, new therapeutic agents are urgently needed. We studied the botanical formula “Li-Hong Tang (LHT)", which contains two main ingredients, Salvia plebeia R. Br and Rhodiola crenulata (Hook. f. et Thoms.) H. Ohba. In this study, we aimed to identify the effects of LHT on UC and explore its potential mechanism.
Methods
LHT was analyzed using a mass spectrometer (MS). DSS at a dose of 2.5% was utilized to develop UC in mice. The administered groups received low, medium, and high dosages (0.32 g/kg, 0.64 g/kg, and 1.28 g/kg) of LHT and the positive medication, sulfasalazine (0.2 g/kg), respectively. Body weight, disease activity index (DAI) score, colon length, spleen index, serum myeloperoxidase (MPO), nitric oxide (NO), superoxide dismutase (SOD) and inflammatory factor concentrations were monitored. The expression of NRF2 and HO-1 in colonic tissues was evaluated by immunohistochemistry. 16S rDNA sequencing was employed to investigate alterations in the gut microbiota of the mice, aiming to elucidate the extent of LHT’s impact.
Results
LHT may ameliorate DSS-induced colitis in mice by lowering inflammation, reducing oxidative stress, restoring the intestinal barrier, and influencing the NRF2/HO-1 pathway. Moreover, LHT treatment exhibited a regulatory effect on the gut microbiota, characterized by elevated levels of Patescibacteria, Verrucomicrobiota, Candidatus_Saccharimonas , Lactobacillus , and Ligilactobacillus levels while decreasing Oscillibacter and Colidextribacte r levels. Further study indicated that MPO, NO, and inflammatory factors were positively correlated with Oscillibacter , Colidextribacter , Escherichia-Shigella , Anaerostines , and negatively with Lactobacillus , Clostridiales_unclassified , Candidatus_Saccharimonas, and Patescibacteria. Furthermore, colony network analysis revealed that Lactobacillus was negatively associated with Oscillibacter and Colidextribacter , whereas Oscillibacter was positively related to Colidextribacter .
Conclusion
LHT protects against DSS-induced mice by inhibiting the inflammatory response, oxidative stress, and mucosal injury. The protective role may involve regulating the NRF2/HO-1 signaling pathway and gut microbiota.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangyin Hospital Affiliated to Nanjing University of Chinese Medicine, Jiangyin, China.
- Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing, China.
Zitieren
APA
Gu, H., Tian, Y., Xia, J., Deng, X., Chen, J., Jian, T., & Ma, J. (2024). Li-Hong Tang alleviates dextran sodium sulfate-induced colitis by regulating NRF2/HO-1 signaling pathway and gut microbiota. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1413666
Vancouver
Gu H, Tian Y, Xia J, Deng X, Chen J, Jian T, et al. Li-Hong Tang alleviates dextran sodium sulfate-induced colitis by regulating NRF2/HO-1 signaling pathway and gut microbiota. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1413666
BibTeX
@article{Gu2024,
author = {Gu, Hong and Tian, Yuwen and Xia, Jingjing and Deng, Xiaoyue and Chen, Jian and Jian, Tunyu and Ma, Jiong},
title = {Li-Hong Tang alleviates dextran sodium sulfate-induced colitis by regulating NRF2/HO-1 signaling pathway and gut microbiota},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1413666}
}
EUVIMED